Scienture Advances Commercial Launch Of FDA-Approved REZENOPY Following Exclusive U.S. Commercialization Agreement

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually

COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided an update on the commercial launch of REZENOPY®.

As previously disclosed, Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. entered into a definitive agreement with Summit Biosciences Inc. (a Kindeva subsidiary) in March 2025, for the exclusive U.S. commercialization rights to REZENOPY® (naloxone HCl) Nasal Spray 10 mg, which received FDA approval on April 19, 2024.

REZENOPY® is a high-strength naloxone HCl nasal spray approved by the FDA. The product leverages the proven use of the naloxone hydrochloride and form factor, with increased effectiveness against potent opioids. IQVIA data (MAT September 2025) indicates a total annual sales of $154 million, unit volume of 9.3 million (eaches) for Naloxone in the US market.